Vesicure Therapeutics Co.

BiotechnologyAngelSuzhou, Chinavesicure.com

Latest round

Angel

Last raised

Sep 2021

Total raised

Undisclosed

Investors

6

About Vesicure Therapeutics Co.

, Ltd is a biopharmaceutical company that focuses on the development of early exosomal drugs. The company engages in the development of early exosomal drugs. Its main product is the research and development platform for innovative exosomes drugs. The company will establish a modEXOTM engineering exosome drug delivery platform.

Who invested in Vesicure Therapeutics Co.

6 investors across 1 round

See all investors in Vesicure Therapeutics Co.

Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.

Funding rounds

  1. Angel

    Sep 17, 2021

    Amount

    Undisclosed

    Investors

    Locked

Questions about Vesicure Therapeutics Co.

Who invested in Vesicure Therapeutics Co.?

Vesicure Therapeutics Co. has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.

How much funding has Vesicure Therapeutics Co. raised?

Vesicure Therapeutics Co. has raised 1 venture round. Sign up free to see how much each round raised and the total.

When did Vesicure Therapeutics Co. last raise money?

Vesicure Therapeutics Co.'s most recent round on record is a Angel, in Sep 2021.

What does Vesicure Therapeutics Co. do?

, Ltd is a biopharmaceutical company that focuses on the development of early exosomal drugs.

Where is Vesicure Therapeutics Co. headquartered?

Vesicure Therapeutics Co. is headquartered in Suzhou, China.

Which VCs invest in companies like Vesicure Therapeutics Co.?

Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back biotechnology companies at Vesicure Therapeutics Co.'s stage. Their profiles are linked below.

Raising like Vesicure Therapeutics Co.? Find the right VCs.

Capital Atlas matches your startup to active investors by stage, sector and region.

Free to start. Upgrade when you're ready to reach out.